Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dorsomorphin dihydrochloride (BML-275 2HCl) 是一种 AMPK 抑制剂 (Ki=109 nM),具有选择性和 ATP 竞争性。Dorsomorphin dihydrochloride 可以抑制 BMP I 型受体 ALK2、ALK3 和 ALK6。Dorsomorphin dihydrochloride 可诱导自噬,具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 189 | 现货 | ||
2 mg | ¥ 258 | 现货 | ||
5 mg | ¥ 466 | 现货 | ||
10 mg | ¥ 685 | 现货 | ||
25 mg | ¥ 1,380 | 现货 | ||
50 mg | ¥ 2,430 | 现货 | ||
100 mg | ¥ 3,630 | 现货 | ||
500 mg | ¥ 8,170 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 466 | 现货 |
产品描述 | Dorsomorphin dihydrochloride (BML-275 2HCl) is an AMPK inhibitor (Ki=109 nM) that is selective and ATP-competitive. Dorsomorphin dihydrochloride inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride induces autophagy, and possesses antitumor activity. |
靶点活性 | AMPK:109 nM (cell free) |
体外活性 |
方法:人肿瘤细胞 HeLa 和 HCT116 用 Dorsomorphin dihydrochloride (1.25-80 μM) 处理 24 h,使用 CCK-8 assay 检测细胞活力。 结果:Dorsomorphin 抑制 HeLa 和 HCT116 细胞的活力,IC50 值分别为 10.71 μM 和 11.34 μM。[1] 方法:ATL 患者来源的 PBMCs 细胞用 Dorsomorphin dihydrochloride (5-25 μM) 处理 24 h,使用 Flow Cytometry 检测细胞凋亡情况。 结果:Dorsomorphin 以剂量依赖的方式增加了急性和慢性型 ATL 患者 PBMC 中早期凋亡细胞的频率。[2] |
体内活性 |
方法:为检测体内抗肿瘤活性,将 Dorsomorphin dihydrochloride (10 mg/kg) 腹腔注射给携带人类肿瘤 S1T 的 NOD/SCID 小鼠,每天一次,持续二十八天。 结果:Dorsomorphin 抑制了 NOD/SCID 小鼠中人 ATL 肿瘤异种移植物的生长。[2] 方法:为检测体内对 SMAD 活性的影响,将 Dorsomorphin dihydrochloride (10 mg/kg) 单次腹腔注射给 iron-dextran 处理的 C57BL/6 小鼠。 结果:Dorsomorphin 消除了 iron-dextran 引起的铁介导的肝脏 SMAD1/5/8 磷酸化的增加。[3] |
激酶实验 | Liver AMPK was partially purified from male SD rats to the blue-Sepharose step. The 100-μl reaction mixture contained 100 μM AMP, 100 μM ATP (0.5 μCi 33P-ATP per reaction), and 50 μM SAMS in a buffer (40 mM HEPES, pH 7.0, 80 mM NaCl, 0.8 mM EDTA, 5 mM MgCl2, 0.025% BSA, and 0.8 mM DTT). The reaction was initiated with the addition of the enzyme. After a 30-minute incubation at 30°C, the reaction was stopped by addition of 80 μl 1% H3PO4. Aliquots (100 μl) were transferred to 96-well MultiScreen plates. The plate was washed three times with 1% H3PO4 followed by detection in a Top-count. The in vitro AMPK inhibition data obtained with compound C — (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a] pyrimidine — were fit to the following equation for competitive inhibition by nonlinear regression using a least-squares Marquardt algorithm in a computer program written by N. Thornberry of Merck Research Laboratories: Vi/Vo = (Km + S)/[S + Km × (1 + I/Ki)], where Vi is the inhibited velocity, Vo is the initial velocity, S is the substrate (ATP) concentration, Km is the Michaelis constant for ATP, I is the inhibitor (compound C) concentration, and Ki is the dissociation constant for compound C [1]. |
细胞实验 | C2C12 cells were seeded into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. Wells were treated in quadruplicate with BMP ligands and dorsomorphin or vehicle. Cells were harvested after 5 d in culture with 50 μl Tris-buffered saline, 1% Triton X-100. Lysates were added to p-nitro-phenylphosphate reagent in 96-well plates for 1 h, and alkaline phosphatase activity expressed as absorbance at 405 nM. Cell viability and quantity were measured by Cell-titer Glo and binding of nuclear dye CyQuant, respectively, using replicate wells treated identically to those used for alkaline phosphatase measurements [3]. |
动物实验 | 12-week-old C57BL/6 mice raised on a standard diet were injected via the tail vein with 0.2 g kg?1 of dextran (average MW = 5,000) or 0.2 g kg?1 of iron-dextran USP. Dextran was injected with vehicle only, whereas iron-dextran was injected with either vehicle or dorsomorphin (10 mg/kg). 1 h after injection, mice were killed and liver segments were collected in 500 μl of SDS-lysis buffer and mechanically homogenized. 20 μl of liver extracts were resolved by SDS-PAGE and immunoblotted. Total RNA was harvested using Trizol from mechanically homogenized mouse livers (6 h after injection with a single intraperitoneal dose of dorsomorphin (10 mg/kg) or DMSO) [3]. |
别名 | BML-275 2HCl, Compound C dihydrochloride, 6-[4-[2-(1-哌啶基)乙氧基]苯基]-3-(4-吡啶基)吡唑并[1,5-A]嘧啶, Dorsomorphin (Compound C) 2HCl, Compound C 2HCl, BML-275 dihydrochloride |
分子量 | 472.41 |
分子式 | C24H25N5O·2HCl |
CAS No. | 1219168-18-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.88 mg/mL (14.55 mM), Sonication is recommended.
H2O: 47.2 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 2.1168 mL | 10.584 mL | 21.1681 mL | 52.9201 mL |
5 mM | 0.4234 mL | 2.1168 mL | 4.2336 mL | 10.584 mL | |
10 mM | 0.2117 mL | 1.0584 mL | 2.1168 mL | 5.292 mL | |
H2O | 20 mM | 0.1058 mL | 0.5292 mL | 1.0584 mL | 2.646 mL |
50 mM | 0.0423 mL | 0.2117 mL | 0.4234 mL | 1.0584 mL | |
100 mM | 0.0212 mL | 0.1058 mL | 0.2117 mL | 0.5292 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dorsomorphin dihydrochloride 1219168-18-9 Autophagy Chromatin/Epigenetic PI3K/Akt/mTOR signaling Stem Cells AMPK TGF-beta/Smad Dorsomorphin (Compound C) Compound C BML 275 BML275 Dihydrochloride Dorsomorphin BMP TGF-β Receptor Compound C Dihydrochloride Dorsomorphin Dihydrochloride inhibit BML-275 2HCl BML-275 Dihydrochloride Compound C dihydrochloride type ATP-competitive BML 275 Dihydrochloride 6-[4-[2-(1-哌啶基)乙氧基]苯基]-3-(4-吡啶基)吡唑并[1,5-A]嘧啶 Dorsomorphin (Compound C) 2HCl Transforming growth factor beta receptors receptors Compound C 2HCl BML-275 dihydrochloride pathway BML-275 AMP-activated protein kinase Inhibitor BML275 inhibitor